Patents Assigned to Sunovion Pharmaceuticals Inc.
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10196399
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 5, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Heteroaryl compounds and methods of use thereof
    Patent number: 10189825
    Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: January 29, 2019
    Assignees: SUNOVION PHARMACEUTICALS INC., PGI DRUG DISCOVERY LLC
    Inventors: John Emmerson Campbell, Una Campbell, Taleen G. Hanania, Liming Shao
  • TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE
    Publication number: 20180333373
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Application
    Filed: January 17, 2018
    Publication date: November 22, 2018
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas Jerussi, Qun Kevin FANG, Mark G. CURRIE
  • Multicyclic compounds and methods of use thereof
    Patent number: 10085968
    Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 2, 2018
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC.
    Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
  • Dosage of dasotraline and method for treatment of ADHD
    Patent number: 10076503
    Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Antony D. Loebel, Kenneth S. Koblan
  • Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    Patent number: 10077243
    Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Preparation of chiral amides and amines
    Patent number: 10011559
    Abstract: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 3, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Hang Zhao, Stefan G. Koenig, Charles P. Vandenbossche, Surendra Singh, Harold Scott Wilkinson, Roger P. Bakale
  • Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
    Patent number: 9994590
    Abstract: Provided herein are substituted [1,2,4]triazlolo[1,5-?]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 12, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: John Emmerson Campbell, Philip G. Jones, Scott Malcolm
  • HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180118727
    Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson CAMPBELL, Una CAMPBELL, Taleen G. HANANIA, Liming SHAO
  • D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
    Patent number: 9951088
    Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 24, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Philip G. Jones, Robert Lew, Kerry L. Spear, Linghong Xie
  • 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS
    Publication number: 20180093974
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 5, 2018
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
    Patent number: 9907764
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 6, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS
    Publication number: 20180057506
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: August 2, 2017
    Publication date: March 1, 2018
    Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Milan CHYTIL, Sharon Engel, Taleen G. HANANIA, Vadim ALEXANDROV, Emer LEAHY
  • Heterocyclic compounds and methods of use thereof
    Patent number: 9884844
    Abstract: Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: February 6, 2018
    Assignee: SUNOVION PHARMACEUTICALS, INC.
    Inventors: Qun Kevin Fang, Una Campbell, Kerry L. Spear
  • Cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9868718
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 16, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
  • 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
    Patent number: 9856238
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 2, 2018
    Assignees: SUNOVION PHARMACEUTICALS INC., PGI DRUG DISCOVERY LLC
    Inventors: Linghong Xie, Philip Glyn Jones, Kerry L. Spear, Noel Aaron Powell, Taleen G. Hanania, Vadim Alexandrov
  • Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors
    Patent number: 9856274
    Abstract: Provided herein are substituted pyrazolopyridine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 2, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Philip Jones, Michael Charles Hewitt
  • Triple reuptake inhibitors and methods of their use
    Patent number: 9850204
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: December 26, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Substituted quinolines as PDE-10 inhibitors
    Patent number: 9834564
    Abstract: Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
  • DOSAGE OF DASOTRALINE AND METHOD FOR TREATMENT OF ADHD
    Publication number: 20170266134
    Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.
    Type: Application
    Filed: May 12, 2015
    Publication date: September 21, 2017
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Antony D. LOEBEL, Kenneth S. KOBLAN